261776-41-4

Basic information

• Product Name: (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine
• Synonyms: (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine
• CAS NO: 261776-41-4
• Molecular Weight: 304.219
• Mol File: 261776-41-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine(261776-41-4)
• EPA Substance Registry System: (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine(261776-41-4)

Safety Data

• Hazardous Substances Data: 261776-41-4(Hazardous Substances Data)

Upstream product

• 95-50-1 1,2-dichloro-benzene 
• 90-15-3 α-naphthol 
• 79617-98-4 (1R,4R)-sertraline 
• 79617-96-2 Sertraline 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 74-89-5 methylamine 

Downstream Products

• 244223-89-0 (cis-1S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine (R)-mandelate 
• 79559-97-0 sertraline hydrochloride 
• 267884-85-5 cis-(1S,4S)-N-(tert-butoxycarbonyl)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 
• 1271002-87-9 C₂₂H₂₅Cl₂NO₂ 
• 140631-53-4 sertraline 
• 1042418-90-5 sertraline 
• 91797-60-3 trans-(1S,4R)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 
• 79617-96-2 Sertraline 
• 79617-89-3 cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine hydrochloride 
• 155748-61-1 (4R)-(3,4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone 
• 79617-98-4 (1R,4R)-sertraline 
• 79951-46-5 trans-(1R,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 
• 124379-29-9 (4S)-4-(3,4-dichlorophenyl)-1-tetralone 

Relevant articles and documents

Asymmetric hydrogenation of N-alkyl and N-aryl ketimines using chiral cationic Ru(diamine) complexes as catalysts: The counteranion and solvent effects, and substrate scope

Asymmetric hydrogenation of N-alkyl and N-aryl ketimines catalyzed by chiral cationic η6-arene-(N-monosulfonylated diamine) Ru(II) complexes has been investigated. Strong counteranion and solvent effects on the enantioselectivity were observed. The ruthenium catalyst bearing non-coordinating BArF- anion was found to be particularly effective for the hydrogenation of acyclic and exocyclic N-alkyl ketimines in the presence of (Boc)2O in dichloromethane or even under solvent-free conditions, providing chiral amines with up to >99% ee and full conversions. Alternatively, the ruthenium catalyst bearing achiral phosphate anion together with corresponding phosphoric acid as the additive was also efficient for the hydrogenation of N-alkyl ketimines in the absence of (Boc)2O with excellent enantioselectivities and full conversions. For N-aryl ketimines lower enantiomeric excesses were observed by using the ruthenium catalyst bearing BArF- anion. This catalytic protocol thus provides a facile and practical access to optically active amines and has been successfully employed in the gram-scale synthesis of enantiomerically pure (+)-sertraline.

PROCESS FOR THE PREPARATION OF [4(S,R)-(3,4-DICHLOROPHENYL)-3,4-DIHYDRO-1(2H)-NAPHTHALEN-1-YLIDENE]METHYLAMINE

The present invention relates to a process for making substantially pure racemic sertraline or its pharmaceutically acceptable salts having a cis/trans ratio of greater than about 85: 15% and which is substantially free of its deschloro impurities. The pr

PROCESSES FOR THE PREPARATION OF SERTRALINE HYDROCHLORIDE

The invention relates to processes for the preparation of Schiff's base, and to the use of Schiff's base as intermediate in the preparation of naphthalenamine derivatives which are active compounds for treating the anxiety related disorders. The invention also relates to processes for the preparation of sertraline or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions that include the sertraline.